You searched for "intravitreal"

533 results found

Clinical trial investigates ‘Light Touch’ approach to wet AMD treatment

A clinical trial led by NIHR Moorfields Clinical Research Facility will explore a new ‘light-touch’ treatment approach for patients with neovascular age-related macular degeneration (wet AMD) that could result in fewer injections and reduced number of clinic visits. Funded by...

Aspiration of anteriorly migrated dexamethasone implant using an 18G intravenous cannula

Intravitreal dexamethasone (Ozurdex 0.7mg) is a biodegradable, sustained-release implant used to manage diabetic macular oedema, macular oedema secondary to retinal vein occlusion, and non-infectious posterior uveitis due to its anti-inflammatory effects and VEGF suppression [1]. While effective, the implant may...

ESASO Course Series (Volume 3): Cataract

T­­­­­his book is designed as a course manual for cataract and refractive surgery. It starts off by discussing both the fluidics and dynamics of phacoemulsification, touching techniques and management of difficult scenarios. The ins and outs of conventional, accommodative, toric...

Pathophysiology of diabetic macular oedema: why combination therapy may be better

The prevalence of diabetes has continued to increase over the years. It is currently estimated that there are 382 million with diabetes worldwide in 2013, and that this figure is expected to rise to 592 million by 2035 [1]. In...

VIBIM Study: One-year results of treatment of DME with aflibercept using TnE

The VIBIM study (the treat-and-extend regimen (TER) using intravitreal aflibercept in diabetic macular edema (DME) study) was designed to evaluate the efficacy of the TER using aflibercept in the management of DME for a period of two years. The authors...

Insights in resistant diabetic macular oedema

This article gives a bird’s eye review of the different modalities for the treatment of diabetic macular oedema (DME). The debut of anti-VEGFs has brought a paradigm shift in DME management. This treatment has now become a major breakthrough in...

Autofluorescence patterns in subretinal haemorrhages associated with neovascular age-related macular degeneration

The aim of this retrospective study was to describe the surgical results and fundus autofluorescence (FAF) patterns occurring in sub-macular haemorrhage (SMH) of duration <60 days in age-related macular degeneration (AMD). Notes from 39 eyes of 39 patients with SMH,...

IVTA for diabetic macular edema and macular edema secondary to retinal vein occlusion: a meta-analysis

This meta-analysis aimed to compare the safety and efficacy of different doses of intravitreal triamcinolone acetonide (IVTA) for diabetic macular oedema (DME) and macular oedema (ME) secondary to retinal vein occlusion (RVO). A systematic literature search for randomised controlled trials...

Cytokine levels in vitreous fluid in patients with pathological myopia

Pathological myopia (PM) is a leading cause of irreversible visual impairment worldwide, and efforts are dedicated to the study of its underlying mechanisms. Axial extension of the eyeball is regulated via a cascade of biochemical molecules that are initiated in...

Variability between handheld fundus cameras

Handheld fundus cameras offer the potential of enhancing opportunities for telemedicine diagnosis of glaucoma, especially in underserved settings, as they are less bulky, inexpensive and don’t require skilled personnel compared to traditional table-mounted retinal cameras. This study aimed to compare...

Treatment of diabetic macular oedema

Diabetic macular oedema (DMO) is a common complication associated with diabetic retinopathy, and the most common cause of visual impairment in diabetes [1]. With predicted rising levels of diabetes (in England by 2025 the estimated population with diabetes will be...

Renewed momentum in ocular gene and cell therapy, broadening application to chronic disease

Gene and cell therapies offer the prospect of ground-breaking new avenues for the treatment of diseases, reflected in a renewed explosion of interest and investment in retinal gene therapy. Rod McNeil reports recent clinical trial readouts across a diverse range...